Yahoo · Oct 2, 2026
GEHC vs. SYK: Which Stock Should Value Investors Buy Now?
GEHC vs. SYK: Which Stock Is the Better Value Option?
NASDAQ · SYK
Stryker Corporation
Healthcare · Medical - Devices
$278.20
Down-$2.80 (-1.01%)
Updated Oct 7, 2026, 10:23 PM
SID Score
4.9/10
Composite research score
Smart Money
47/100
Neutral
- Market cap
- 134.97B
- P/E ratio
- 45.86
- Dividend yield
- 1.21%
- 52-week range
- $267.00 – $389.33
- Volume
- 2.86M
- Avg. volume
- 1.61M
Price performance · SYK
SYK price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
SYK closed at $278.20 after 21 trading sessions, up 0.64% for the selected period.
- Last close
- $278.20
- Period change
- +0.64%
- Period low
- $269.75
- Period high
- $285.22
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $279.37 | $284.53 | $277.10 | $278.20 | 2.86M |
| Oct 5, 2026 | $275.50 | $286.09 | $275.00 | $285.22 | 3.33M |
| Oct 2, 2026 | $273.185 | $276.97 | $271.213 | $275.43 | 2M |
| Oct 1, 2026 | $275.60 | $278.51 | $271.341 | $272.96 | 2.46M |
| Sep 30, 2026 | $276.26 | $279.372 | $273.05 | $275.39 | 2.93M |
| Sep 29, 2026 | $277.00 | $280.165 | $274.305 | $278.77 | 2.79M |
| Sep 28, 2026 | $273.50 | $276.94 | $271.10 | $275.31 | 2.49M |
| Sep 25, 2026 | $269.93 | $275.84 | $268.69 | $272.36 | 2.34M |
| Sep 24, 2026 | $273.22 | $275.7142 | $269.725 | $269.75 | 2.29M |
| Sep 23, 2026 | $274.46 | $277.1035 | $271.445 | $273.40 | 2.72M |
| Sep 22, 2026 | $277.00 | $278.99 | $274.99 | $275.09 | 2.36M |
| Sep 21, 2026 | $274.58 | $276.868 | $272.00 | $274.19 | 2.76M |
| Sep 18, 2026 | $278.02 | $279.26 | $274.37 | $275.12 | 4.81M |
| Sep 17, 2026 | $286.10 | $286.125 | $279.09 | $280.13 | 2.37M |
| Sep 16, 2026 | $280.34 | $290.51 | $279.875 | $284.76 | 3.4M |
| Sep 15, 2026 | $281.00 | $282.69 | $277.62 | $281.50 | 3.46M |
| Sep 14, 2026 | $282.31 | $287.165 | $280.67 | $281.87 | 2.94M |
| Sep 11, 2026 | $270.72 | $277.00 | $267.00 | $275.56 | 3.72M |
| Sep 10, 2026 | $274.62 | $278.00 | $269.64 | $270.01 | 3.48M |
| Sep 9, 2026 | $271.835 | $278.745 | $270.85 | $275.39 | 5.5M |
| Sep 8, 2026 | $301.00 | $301.505 | $275.10 | $276.43 | 6.32M |
Latest SYK news
The latest Smart Investors Daily articles mentioning SYK.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SYK research
Overview
Company profile and research snapshot.
Company profile
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $419.33
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Stifel | Buy | — |
| Sep 22, 2026 | TD Cowen | Hold | — |
| Sep 18, 2026 | Canaccord Genuity | Buy | — |
| Sep 10, 2026 | Citigroup | Buy | — |
| Sep 9, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 30, 2026
Stifel Maintains Buy on Stryker, Lowers Price Target to $330
Stifel analyst Rick Wise maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $360 to $330.
SeekingAlpha · Sep 28, 2026
An Investor's Guide To Switching Costs
Switching costs provide a company with the leverage to increase prices and deliver hefty profits over time. Read more here.
Yahoo · Sep 25, 2026
ELFA Names James Cress Acting President & CEO
WASHINGTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- The Equipment Leasing & Finance Association (ELFA) announced that its Board of Directors has selected James Cress, ELFA’s Immediate Past Chair, to serve as Acting President & CEO while the Association searches for its next permanent President & CEO. This decision follows ELFA’s earlier announcement that President & CEO Leigh Lytle would conclude her tenure with the Association later this year. “I am so pleased that James has agreed to serve as Actin
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
